Lung Cancer Diagnostics Market Key Players Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts

Lung Cancer Diagnostics Market Size and Forecast 2025-2033

The Lung Cancer Diagnostics Market is expected to witness significant growth, reaching US$ 38.00 billion by 2033 from US$ 21.74 billion in 2025, at a CAGR of 7.23% during the forecast period of 2025 to 2033. Some of the major factors responsible for the market growth include an increasing number of public access facilities, a rise in ambulance services, and an increasing prevalence of cardiac disorders such as coronary artery diseases and arrhythmias.

Lung cancer diagnosis refers to the various techniques and technologies that may be employed for the detection and assessment of lung cancer in humans. This may involve chest X-rays, computed tomography scans, MRI, biopsies, and blood analyses. The objectives are the accurate identification of cancer at its earliest moment-that is most conducive to effective therapy and better outcomes.

Lung cancer diagnostic tests are popular worldwide since the prevalence of the disease has risen in both smokers and environmental pollutant-exposed populations. Due to increasing awareness of risks, people are turning up for early screening and diagnostic services. Medical technology is also improving day by day, creating better imaging and detection techniques that improve survival rates.

Moreover, public health campaigns for awareness about lung cancer have contributed to increased demand for diagnostics. Therefore, health systems worldwide are focusing on the need for early detection, and diagnostics of lung cancer have now become an integral part of strategies for the care and management of the disease in different populations.

Top 5 Companies in the Lung Cancer Diagnostics Market by 2033

1. Illumina, Inc.

Founding: 1998

Headquarters: United States of America

Illumina Inc. is a leading genomic sequencing and array-based technologies provider utilized for genetic analysis in consumer genomics, translational genomics, cancer research, and molecular diagnostics. The broad product portfolio consists of sequencing systems and tools, microarray kits and sequencing kits, molecular biology reagents, and corresponding consumables. Illumina also provides services for whole-genome sequencing, microarray analysis, as well as instrument consulting, maintenance, and training. Pharmaceutical and biotechnology corporations, universities and research institutions, clinical research groups, and genomics research organizations are the typical customers. Illumina distributes its products through a blend of direct marketing and distribution networks across various geographies such as the Americas, Europe, Asia-Pacific, Middle East, and Africa.

2. Abbott Laboratories

Headquarters: United States of America

Founded: 1888

Abbott Laboratories develops, manufactures, and sells a wide range of medical and health care products, including nutritionals and diagnostics. The company develops products mainly for gastroenterology and women's health, while its other key areas of operations include cardiovascular and metabolic health, pain management, and central nervous system disorders. Abbott will also manufacture respiratory drugs and vaccines, biosimilars, core laboratory systems, and transfusion medicine technologies. The product portfolio will further comprise point-of-care systems, rapid diagnostic lateral flow tests, informatics and automation solutions, nutritional products, and rhythm management, electrophysiology, and heart failure-related devices. Abbott deals with a wide range of vascular and structural heart needs and neuromodulation therapies. Its products are sold to wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and independent retailers in North America, Latin America, the Middle East, Europe, Asia-Pacific, and Africa.

3. Thermo Fisher Scientific Inc.

Establishment: 2006

Headquarters: United States of America

Thermo Fisher Scientific Inc. has emerged as one of the global leaders in providing analytical instruments, life sciences solutions, specialty diagnostics, and laboratory services. Its product portfolio includes laboratory equipment, instruments, clinical diagnostic products, chromatography and mass spectrometry systems, chemicals, cell culture products, and molecular biology products. Thermo Fisher markets its products to pharmaceutical and biotechnology firms, hospitals, clinical laboratories, academic research institutions, and government agencies. The major brands of the company are Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. The company sells its products through a worldwide direct sales and customer service professional network, e-commerce websites, and third-party distributors.

4. QIAGEN N.V.

Founding: 1984

Head Office: Netherlands

Qiagen NV (Qiagen) is a worldwide provider of molecular testing solutions. Qiagen supplies technologies used for the extraction and processing of proteins, DNA, and RNA from different sample materials, including blood and tissues. Qiagen builds assay technology to detect genetic data in tumours and pathogens, and also bioinformatics applications for interpreting advanced genomic data. Its automation tools automate molecular tests procedures in a lab. Qiagen caters to a wide variety of markets such as human healthcare, veterinary diagnostics, forensics, food safety, pharmaceuticals and life sciences research. Products are sold directly, as well as through independent distributors. The company is located in the Americas, Europe, the Middle East, Africa, and Asia-Pacific.

5. F. Hoffmann-La Roche Ltd.

Establishment: 1896

Headquarters: Switzerland

F. Hoffmann-La Roche Ltd. is the leading global biotechnology company in in-vitro diagnostics and pioneered innovative solutions in major disease areas. It develops and supplies medicines for cancer, autoimmune diseases, central nervous system disorders, eye diseases, infectious diseases, and respiratory diseases. The company also provides solutions for in-vitro diagnosis, tissue-based cancer diagnosis, and diabetes care. It undertakes active research and development activities with a strategic aim of finding new ways to prevent, diagnose, and treat several diseases. Roche supplies its entire range of products and services to hospitals, doctors and healthcare professionals, laboratories for commercial purposes, researchers, and pharmacists.

Product Launches in the Lung Cancer Diagnostics Market

Sanofi S.A.

Fresolimumab, developed by Sanofi, is at present under development and in the Phase II stage of clinical trials for NSCLC. Drugs in Phase II of NSCLC treatment have a benchmark phase transition success rate (PTSR), as estimated by GlobalData, of 38% to proceed to Phase III trials.

Agilent Technologies

In March 2025, Agilent Technologies Inc. announced that its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding treatment eligibility to early-stage NSCLC and previously untreated advanced melanoma patients. These two indications bring the total indications launched in Europe for the PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is indicated for use on the Agilent Autostainer Link 48 advanced staining solution exclusively.

SWOT Analysis of Company

bioMerieux.

Strength - Proven Expertise in Molecular and Biomarker-Based Diagnostic Technologies

The biggest strength of bioMerieux within the lung cancer diagnostics market is its extensive expertise in molecular diagnostics and biomarker detection technologies. With experience in clinical microbiology and oncology diagnostics for decades, the company has a leading position in precision testing and advanced assay development. Its capabilities with molecular platforms-PCR-based systems, NGS integration, immunoassays-allow for the identification of cancer biomarkers and genetic mutations linked to lung cancer with accuracy. Therefore, leveraging its global presence and established partnerships with hospitals, research institutions, and biotechnology organizations will further enhance its ability to translate scientific innovations into clinically validated diagnostic tools. In addition to that, strong attention to quality, regulatory compliance, and reliability of data fortify the clinician's confidence and patient outcomes. Taken together, this technological expertise, clinical credibility, and global infrastructure positions bioMerieux to become a trusted leader in driving early, precise, and personalized diagnostics of lung cancer worldwide.

Myriad Genetics, Inc.

Strength - Leadership in Genetic Testing and Precision Oncology

Myriad Genetics, Inc.'s key strength in the lung cancer diagnostics market is its leading role in genetic and molecular testing for precision oncology. The company has significant expertise and experience in identifying hereditary and somatic cancer mutations, hence developing high-accuracy diagnostic assays for targeted lung cancer therapies. The robust bioinformatics of Myriad coupled with its proprietary databases enable the high degree of precision needed in the interpretation of complex genomic data to provide clinicians with actionable insights toward personalized treatment decisions. Thus, its portfolio of validated molecular diagnostic products, including companion diagnostic tests, is well integrated into clinical oncology workflows. Moreover, Myriad's strong research collaborations with pharmaceutical companies and cancer research centers accelerate biomarker discovery and therapy matching. Combining this with its genetic expertise, data-driven precision, and clinical integration means that Myriad Genetics stands at the forefront of personalized medicine and improves outcomes not only in lung cancer diagnostics but in treatment selection as well.

Recent Development in the Lung Cancer Diagnostics Market

Siemens Healthineers AG

The International Atomic Energy Agency has teamed up with Siemens Healthineers to strengthen diagnosis and treatment capabilities in low- and middle-income countries. This collaboration seeks to unlock new ways in which the technical expertise of each organization can be applied to combat the increasing global burden of cancer, which claims millions of lives each year. The agreement will be implemented through the IAEA's Rays of Hope initiative, which is aligned with Siemens Healthineers and its Varian oncology business mission to improve access to quality healthcare for everyone, everywhere. Both initiatives support United Nations Sustainable Development Goal 3, which aims at reducing premature mortality from non-communicable diseases by a third by 2030.

Danaher Corporation

July 17, 2024, Danaher Corporation, a global science and technology innovator, announced the opening of two new CLIA and CAP-certified labs dedicated to accelerating Companion Diagnostics and Complementary Diagnostics development. These CDx and CoDx tests allow patients to access targeted therapies that are intended to better treat their disease. CDx tests are designed to determine if a patient produces enough of a particular protein to respond well to a certain drug. CoDx tests highlight broadly which type of therapy may be most helpful for a patient. For patients receiving cancer treatment, this diagnostic process can make all the difference in terms of prognosis.

Sustainability Goal

Guardant Health, Inc.

At Guardant Health, Inc., the corporate vision of sustainability centers on transforming cancer treatment through innovative precision oncology, while continuing to conduct operations in a manner that ensures a strong commitment to environmental, social, and governance principles. It seeks to make early cancer detection and advanced genomic testing widely available to improve health outcomes and lower the economic burden of late-stage disease treatment worldwide. Environmentally, Guardant Health is focused on responsible laboratory practices, minimizing waste, and efficient resource management in its testing facilities. Its approach toward social aspects involves fostering an inclusive, diverse workplace and investing in community health initiatives that create awareness about cancer and provide equitable diagnostics. It also upholds high ethical standards related to data privacy and transparency of clinical research. By combining its commitment to sustainability with its drive to be innovative, the company strives for the creation of long-term value: to improve lives through earlier detection of cancer, while ensuring that its operations are beneficial to society and the environment.

Veracyte, Inc.

Sustainably improving global health outcomes through innovative genomic diagnostics while conducting responsible and sustainable operations is the core of Veracyte, Inc.'s sustainability goal. The company reduces healthcare waste and inefficiency by enabling the earlier and more accurate diagnosis of diseases, especially in oncology and pulmonology, thus minimizing unnecessary procedures and treatments. In relation to the environment, it works on reducing its carbon footprint by utilizing responsible practices in laboratory operations, energy-efficient facilities, and sustainably sourced materials. The Company promotes diversity, equity, and inclusion within its staff because diverse points of view can drive scientific innovation along with social progress. Veracyte practices the highest possible standards regarding clinical data management, patient privacy, and research integrity. The commitment will be to responsible innovation, transparency, and community engagement in developing sustainable, long-term value: to advance precision medicine and ensure growth aligned with global environmental and social sustainability objectives for a healthier, more equitably served world.

Market Segmentations

Lung Cancer Diagnostics Market

• Historical Trends
• Forecast Analysis

Market Share Analysis - Lung Cancer Diagnostics Market

llumina, Inc.

Overview

• Company History and Mission
• Business Model and Operations
• Workforce

Key Persons

• Executive Leadership
• Operational Management
• Division Leaders
• Board Composition

Recent Development & Strategies

• Mergers & Acquisitions
• Partnerships
• Investments

Sustainability Analysis

• Renewable Energy Adoption
• Energy-Efficient Infrastructure
• Use of Sustainable Packaging Materials
• Water Usage and Conservation Strategies
• Waste Management and Circular Economy Initiatives

Product Analysis

• Product Profile
• Quality Standards
• Product Pipeline
• Product Benchmarking

Strategic Assessment: SWOT Analysis

• Strengths
• Weaknesses
• Opportunities
• Threats

Revenue Analysis

The above information will be available for all the following companies:

1. llumina, Inc.

2. Abbott Laboratories

3. Thermo Fisher Scientific, Inc.

4. QIAGEN N.V.

5. Roche Holding AG.

6. Sanofi S.A.

7. Agilent Technologies

8. bioMerieux.

9. Myriad Genetics, Inc.

10. Siemens Healthineers AG

11. Danaher Corporation

12. Guardant Health, Inc.

13. Veracyte, Inc.

14. Natera, Inc.

15. GE HealthCare

16. MedGenome

17. NanoString Technologies, Inc.